FDA Warns of Miscarriage Risk from Yeast Infection Drug Diflucan

Thursday, May 12, 2016

The Food and Drug Administration recently added a strong warning to the yeast infection drug Diflucan for women who are pregnant, saying that even small doses have been associated with a higher risk of miscarriage.

Diflucan, taken orally, was approved by the FDA in 1990 and is sold by Pfizer. It is prescribed for a variety of fungal infections in the lungs, bladder, esophagus, mouth and blood, and is also indicated to fight infections in those with cancer or weakened immune systems. But it is used most often for vaginal yeast infections.

The agency had previously warned that the drug may cause a higher incidence of certain birth defects when taken during the first trimester, however, this is the first warning to address miscarriages.


Danish Study Shows Diflucan Miscarriage Link

The April 26 FDA warning came after a study out of Denmark found that women who took Diflucan from between the 7th and 22nd week of pregnancy for yeast infections had “significantly” higher chances of miscarriage.

And, in most cases, patients in the study had only used the recommended dose of 150 mg once or twice.

Now, the FDA will launch its own investigation to further examine the Danish study, as well as other available clinical data.


2011 FDA Warning About Diflucan Birth Defects

This isn’t the first warning to surface about the use of Diflucan during pregnancy. In 2011, the FDA warned that extended use of the 400 to 800 mg dosages of the drug during the first trimester could be linked to birth defects of the skull and cleft palate, among others.

The drug currently carries a label warning for such birth defect risks, but does not mention anything about miscarriages.


FDA Recommends Caution in Prescribing Diflucan

At this time, the FDA recommends that doctors use caution in prescribing Diflucan to women who are pregnant, until such time as the agency can complete its review. Those who are currently pregnant or are trying to become pregnant are advised to speak with their doctor about other treatment options.

It is important to note that the Centers for Disease Control and Prevention advises that women who are pregnant only be prescribed topical antifungal products for vulvovaginal yeast infections, not oral ones.

Lawyers are currently investigating whether Pfizer had prior information about the risk of miscarriages in pregnant women who took the drug but didn’t warn patients. If so, they may be liable for damages to those families affected.

For more information on the current warnings and side effects related to Diflucan, or to speak with a lawyer, contact DrugNews today.



FDA Drug Safety Communication: FDA Evaluating Study Examining Use of Oral Fluconazole (Diflucan) in Pregnancy. (April 26, 2016). Retrieved from www.fda.gov

Lowes, R. Low-Dose Fluconazole in Pregnancy Worries FDA. MedScape. (April 26, 2016). Retrieved from www.medscape.com


Other drugs and devices in the news:

Tuesday, April 14, 2020
Sudden Rise in Elmiron Eye Disease Cases Raises Questions

Elmiron is a mild blood-thinner drug that has been around since 1996 and is prescribed to treat bladder pain or inflammation, a condition called interstitial cystitis.

Monday, April 13, 2020
Asbestos Mesothelioma
Estimated $30 Billion Left Unclaimed in Asbestos Victim Funds

Since many of the companies that sold asbestos or used it in their products have long since gone out of business, people who are diagnosed with asbestos-related cancers often think it’s too late to file a lawsuit.

Get in touch with us.

Call, email or live chat with us today to see how we can help.

call DrugNews.net
Need a quick answer? Call us!
email DrugNews.net
Reach out to us by email.
live chat with DrugNews
We are here to help now